Domain Structure of Rat 10-Formyltetrahydrofolate Dehydrogenase
RESOLUTION OF THE AMINO-TERMINAL DOMAIN AS 10-FORMYLTETRAHYDROFOLATE HYDROLASE*

(Received for publication, October 23, 1996, and in revised form, February 5, 1997)

Sergey A. Krupenko Dagger §, Conrad Wagner Dagger and Robert J. Cook Dagger

From the Dagger  Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, Tennessee 37232 and the  Research Service, Department of Veterans Affairs Medical Center, Nashville, Tennessee 37212

ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
FOOTNOTES
REFERENCES


ABSTRACT

We expressed the NH2-terminal domain of the multidomain, multifunctional enzyme, 10-formyltetrahydrofolate dehydrogenase (FDH), using a baculovirus expression system in insect cells. Expression of the 203-amino acid NH2-terminal domain (residues 1-203), which is 24-30% identical to a group of glycinamide ribonucleotide transformylases (EC 2.1.2.2), resulted in the appearance of insoluble recombinant protein apparently due to incorrect folding. The longer NH2-terminal recombinant protein (residues 1-310), which shares 32% identity with Escherichia coli L-methionyl-tRNA formyltransferase (EC 2.1.2.9), was expressed as a soluble protein. During expression, this protein was released from cells to the culture medium and was purified from the culture medium by 5-formyltetrahydrofolate-Sepharose affinity chromatography followed by chromatography on a Mono-Q column. We found that the purified NH2-terminal domain bears a folate binding site, possesses 10-formyltetrahydrofolate hydrolase activity, and exists as a monomer. Titration of tryptophan fluorescence showed that native FDH bound both the substrate of the reaction, 10-formyl-5,8-dideazafolate, and the product of the reaction, 5,8-dideazafolate, with the same affinities as its NH2-terminal domain did and that both proteins bound the substrate with a 50-fold higher affinity than the product. Neither the NH2-terminal domain nor its mixture with the previously purified COOH-terminal domain had 10-formyltetrahydrofolate dehydrogenase activity. Formation of complexes between the COOH- and NH2-terminal domains also was not observed. We conclude that the 10-formyltetrahydrofolate dehydrogenase activity of FDH is a result of the action of the aldehyde dehydrogenase catalytic center residing in the COOH-terminal domain on the substrate bound in the NH2-terminal domain and that the intermediate domain is necessary to bring the two functional domains together in the correct orientation.


INTRODUCTION

The amino-terminal sequence (residues 1-203) of the tetrameric multifunctional enzyme, 10-formyltetrahydrofolate dehydrogenase (FDH)1 (EC 1.5.1.6) is 24-30% identical to glycinamide ribonucleotide transformylase (GAR-transformylase) (EC 2.1.2.2) from different species (1). There is also a 32% identity (2) (residue 1-310) to Escherichia coli L-methionyl-tRNA formyltransferase (MFT) (EC 2.1.2.9) (3). The NH2-terminal domain of FDH presumably contains a folate binding site. The sequence HPSLLP (residues 106-111) and a glycine (residue 115) four residues downstream were predicted to be the key motif for the 10-FTHF binding (1). This motif is strictly conserved among a large number of enzymes that use 10-FTHF as a formyl donor. No direct evidence has been obtained, however, that this sequence is responsible for folate binding. The structure of a complex between E. coli GAR-transformylase and a multisubstrate adduct, part of which imitates 10-FTHF, was recently resolved (4). It was found that His108 of this conserved motif in GAR-transformylase (which corresponds to His106 of FDH) might participate in folate binding through formation of a hydrogen bond with the oxygen of the formyl group (4). Later experiments based on site-directed mutagenesis led to the conclusion that this histidine is not absolutely required for catalytic function (5).

In the absence of NADP+, FDH hydrolyses 10-FTHF to THF and formate (6, 7). Presumably, the NH2-terminal domain of FDH is responsible for this hydrolase activity. An enzyme, formyltetrahydrofolate hydrolase, which also catalyzes the hydrolysis of 10-FTHF to THF and formate was recently found in E. coli (8). This enzyme is activated by methionine and inhibited by glycine (9). It is composed of 280 amino acid residues; the sequence from residues 84 to 280 exhibits 27% identity with GAR-transformylase (8) while the sequence from residues 1 to 84 serves as a regulatory domain, which binds methionine and glycine (8, 9). The enzyme contains the sequence HHSFLP and a glycine four residues downstream (see Fig. 1) that is similar to the possible 10-FTHF binding motif mentioned above with just two substitutions, proline for histidine and leucine for phenylalanine. Despite their similar catalytic function, identity of the sequence of formyltetrahydrofolate hydrolase (residues 84-280) with the NH2-terminal domain of FDH (residue 1-197) does not exceed 20%, and most of the identity is connected with the putative 10-FTHF binding motif and sequence adjacent to aspartate 142, which was also predicted to participate in the substrate binding (Fig. 1). In addition, FDH has no regulatory domain. Therefore, while the hydrolase can regulate the pools of 10-FTHF and THF in response to the methionine/glycine ratio (9), such a regulatory role looks unlikely for FDH.


Fig. 1. Sequence alignment of the NH2-terminal domain of FDH and E. coli formyltetrahydrofolate hydrolase. The alignment was achieved with GENALIGN (Intelligenetics Inc.) using the Needleman-Wunsch algorithm (22). Identical residues are indicated by vertical lines, and conservative changes are shown as +. Rat FDH sequence of residues 1-197 was taken from Swiss-Prot P28037[GenBank]. The E. coli formyltetrahydrofolate hydrolase (FH) sequence was taken from GenBankTM L20251[GenBank]. The putative 10-FTHF binding motif is in boldface type.
[View Larger Version of this Image (24K GIF file)]


Using limited proteolytic digestion of rabbit liver FDH, Schirch et al. have shown that the hydrolase activity of the enzyme is associated with a 32-kDa NH2-terminal domain (10). As a result of studies employing fluorescence and isothermal titration calorimetry, these investigators also reported that the enzyme contains only one folate binding site per tetramer. This differs from an earlier report from our laboratory using covalent addition of folate that found two folates bound per monomer or eight per tetramer (11).

Recently, we expressed the COOH-terminal domain of FDH (residues 420-902), which is about 48% identical to a group of aldehyde dehydrogenases (12). This recombinant peptide was a functional protein displaying aldehyde dehydrogenase activity and bearing an NADP+ binding site. It was perhaps not surprising that the COOH-terminal domain could be folded into a functional protein because of the high homology with aldehyde dehydrogenase and the presence of aldehyde dehydrogenase activity in native FDH. In the case of the NH2-terminal domain, it is difficult to predict whether this domain itself can fold into a functional protein as it has significantly less identity with any natural proteins. Nevertheless, expression and study of protein fragments often provide important information about protein structure and function. Therefore, in the present study, we expressed the NH2-terminal domain of FDH to learn whether this domain is able to fold independently of the other two domains into a functional enzyme having formyltetrahydrofolate hydrolase activity and to investigate its properties.


MATERIALS AND METHODS

Materials used, protein expression, assay of enzyme activity, fluorescence studies, analysis of kinetic data, and protein molecular size determination are described in the accompanying article (12).

Vector Construction

To prepare the construct for expression of the 203-amino acid NH2-terminal protein, the terminal codon, TAG, was introduced into the FDH sequence cloned into the vector, pVL1393, (13) immediately after isoleucine 203. The codon, CAG, corresponding to glutamine 204 in the sequence of FDH was changed to a TAG stop codon using the Transformer site-directed mutagenesis kit (Clontech, Palo Alto, CA). Two oligonucleotides were used, the mutagenic oligonucleotide 5'-CTATGAGGGCATCAAGAAGGAGA-3' for introduction of the mutation in the FDH sequence (stop codon is underlined) and a selection oligonucleotide 5'-GAATTCCGGAGCTGCAGATC-3' for conversion of one unique restriction site, XmaIII, to StuI (underlined), which was also unique, in pVL 1393.

To construct the vector for expression of the 310-amino acid residue NH2-terminal domain, we removed the coding sequence between the NheI and ScaI restriction sites (amino acids 311-902) from the vector used for expression of FDH (13). This was done in several steps. First, we removed from pVL 1393, with the FDH sequence inserted, one of the two ScaI restriction sites (residing in the ampicillin resistance region) by site-directed mutagenesis. The Transformer site-directed mutagenesis kit, mutagenic oligonucleotide 5'-GACTGGTGCAACCAAG-3' that altered nucleotide T to C (bold) in the ScaI restriction site (former ScaI restriction site is underlined), and the selection oligonucleotide was used in the experiment. The mutated plasmid was cut with NheI restriction endonuclease (that removed the sequence corresponding to amino acid residues 310-504 between the two NheI restriction sites) and was treated for 15 min with Mung bean nuclease (Promega, Madison, WI) to create blunt ends. Then the linear plasmid was cut with ScaI restriction endonuclease (that removed the sequence corresponding to amino acids 505-902) and was ligated through internal blunt ends.

The mutagenic experiments were carried out according to the Clontech protocol. The sequence of the constructs was confirmed by sequencing on model 373A fluorescence sequenator (Applied Biosystems).

Purification of the Recombinant Protein

All buffers used in purification steps contained 10 mM 2-ME and 1 mM NaN3. FDH was purified as described earlier (13). The 310-amino acid NH2-terminal domain was purified from the cell-free culture medium by affinity chromatography on a column of 5-formyltetrahydrofolate-Sepharose (14, 15). A column (1.5 × 10 cm) was packed with about 8.0 ml of settled gel and equilibrated with 10 mM Tris-HCl buffer, pH 7.4 (buffer 1). Medium (200 ml), plus 2-ME (10 mM) and NaN3 (1 mM) was applied to the affinity column. The column was then washed with buffer 1 (100 ml). The enzyme was eluted from the column with buffer 1 containing 1 M NaCl. The eluate was passed through a column of Bio-Gel P6-DG (Bio-Rad) equilibrated with buffer 1 to remove salt. The eluate was concentrated to approximately 5 ml using an Amicon, Inc. (Beverly, MA) filtration cell. Additional purification was done on a Mono-Q column with a linear NaCl gradient (0-1.0 M in buffer 1) using an FPLC system (Pharmacia Biotech Inc., Piscataway, NJ).


RESULTS

Expression and Purification of NH2-terminal Domain

Two different length peptides were expressed, one containing the first 203 amino acids from the NH2 terminus and the other containing the first 310 amino acids. The expressed 203-amino acid length protein was present only in the cells but not in the medium even in the very late postinfection period (data not shown). This is unlike the results obtained when recombinant FDH (13) and its COOH-terminal domain were expressed (12) where most of the enzyme was found in the medium. Attempts to purify the protein from the cells showed that the expressed 203-amino acid length NH2-terminal peptide was insoluble and was not purified or characterized.

In contrast, the recombinant NH2-terminal 310-amino acid polypeptide was found to be present in both cells and culture medium (Fig. 2), similar to the full-length enzyme (13) and its COOH-terminal domain (12). To purify this protein, we used affinity chromatography on a 5-formyltetrahydrofolate-Sepharose column. This procedure was effective for isolation of the 310-amino acid NH2-terminal domain from both the cell lysate (data not shown) and the culture medium (Fig. 3). The recombinant protein was bound by the affinity column and retained during washing with low salt buffer. The protein was completely eluted from the column by 1.0 M NaCl. Additional elution with 20 mM folate revealed only trace amounts of the protein. Further purification was done by chromatography on a Mono-Q column (Fig. 3). The peak containing the NH2-terminal domain was eluted at 0.27 M NaCl, pooled, and stored at 4 °C.


Fig. 2. Expression of the 310-amino acid residue NH2-terminal domain of FDH. The NH2-terminal domain was detected by SDS-PAGE with Coomassie staining (top) and by immunoblotting with specific antiserum against FDH (bottom) in culture medium and in the cell extract. St, protein standards (phosphorylase b, 94 kDa; bovine serum albumin, 67 kDa; ovalbumin, 43 kDa, carbonic anhydrase, 30 kDa; and soybean trypsin inhibitor, 20.1 kDa). Position of the NH2-terminal domain (shown by arrows) corresponded to its molecular mass of 34 kDa. Numbers on top of the gel show days postinfection (DPI).
[View Larger Version of this Image (99K GIF file)]



Fig. 3. SDS-PAGE of NH2-terminal domain at different purification steps. Shown are culture medium, lane 1; preparation after affinity chromatography on a 5-formyltetrahydrofolate-Sepharose column, lane 2; preparation after affinity chromatography and chromatography on Mono-Q column, lane 3; and protein standards as in Fig. 2, lane St. About 5 µg of total protein was loaded per lane.
[View Larger Version of this Image (43K GIF file)]


Properties of the NH2-terminal Domain

Initial studies showed that the 310-amino acid NH2-terminal domain was able to hydrolyze both 10-FTHF and 10-FDDF. For further study on this protein, we used the dideaza analog, which is much more stable and has been shown to replace the natural substrate in enzymatic reactions carried by FDH (16). Kinetic parameters of the reaction for the NH2-terminal domain were similar to those for the native enzyme with Km values of 7.3 and 5.8 µM and Vmax values of 99 and 80 nmol min-1 mg-1 (kcat of 3.5 and 8.0 min-1/protein monomer), respectively. Addition of NADP+ did not change the velocity of the hydrolase reaction, and no increase in absorbance at 340 nm was observed showing no reduction of NADP+ to NADPH. This showed that the NH2-terminal domain does not possess dehydrogenase activity. To check whether the NH2-terminal domain has a binding site for the coenzyme, we titrated the quenching of tryptophan fluorescence with NADP+. No changes in fluorescence of the NH2-terminal domain were observed in the presence of NADP+ (data not shown). In contrast, fluorescence of the full-length enzyme (17) and its COOH-terminal domain (12) was decreased 25-30% in the presence of NADP+.

It has been shown that the hydrolase reaction performed by FDH is dependent on the presence of 2-ME (2, 16). To study whether the NH2-terminal domain requires the presence of 2-ME, we measured the velocity of the reaction in the presence of varying concentrations of 2-ME. It was observed that the reaction is strictly dependent on the presence of 2-ME (Fig. 4). Moreover, the reaction requires relatively high concentrations of 2-ME as the velocity was still going up at 100 mM of 2-ME (Fig. 4).


Fig. 4. Dependence of hydrolase activity on the concentration of 2-ME. Hydrolase activity of FDH and its NH2-terminal domain was assayed as described (12) in the presence of different concentrations of 2-ME.
[View Larger Version of this Image (32K GIF file)]


The pH-dependence of the hydrolase reaction was measured for both FDH and its NH2-terminal domain. This was carried out using two buffer systems, potassium phosphate (pH 4.5-9.0) and acetate (pH 3.0-5.0). No difference in the activity was found between the two buffer systems in the overlapping pH range. The pH dependence of the hydrolase reaction was similar for both FDH and its 310-amino acid NH2-terminal domain with a very broad reaction maximum (Fig. 5).


Fig. 5. pH dependence of hydrolase reaction. Hydrolase activity of FDH (closed circles) or its NH2-terminal domain (open circles) was assayed as described (12) in phosphate (pH 4.55-9.0) or acetate (pH 3.0-5.0) buffer.
[View Larger Version of this Image (14K GIF file)]


Folate Ligand Binding Study

We used titration of tryptophan fluorescence to investigate differences in ligand binding between FDH and the 310-amino acid NH2-terminal domain. The fact that the hydrolase reaction does not proceed in the absence of 2-ME and the dehydrogenase reaction requires the presence of NADP+ allowed us to specifically measure ligand binding in the absence of both compounds since no reaction can take place. This was done with the substrate 10-FDDF and the reaction product DDF. The tryptophan fluorescence of both FDH and the NH2-terminal domain was decreased by about 50% when either 10-FDDF or DDF was bound (data not shown). The affinity for the substrate was 50-fold higher than the affinity for the product (Fig. 6) with dissociation constants of 6 and 300 nM, respectively. No significant difference in the affinity between FDH and NH2-terminal domain was observed (Fig. 6). We also studied the influence of 2-ME on the binding of 10-FDDF and DDF to the proteins. Because the Kd for 10-FDDF is about three orders of magnitude less than the Km in the hydrolase reaction, the addition of 2-ME did not evoke substrate decomposition in the concentration range studied, and we were able to measure binding in the presence of 2-ME. We did not see any differences in affinity of FDH and the NH2-terminal domain for either 10-FDDF or DDF in the presence of 2-ME (data not shown).


Fig. 6. Fluorescence data for ligand binding plotted in linear form. The value (1 - F/Fo)-1 was plotted against the inverse of ligand concentration (23). This is a modified form of the classical Stern-Volmer plott, which relates the drop in fluorescence to the concentration of a collisional quencher (for review, see Ref. 24). F is intrinsic fluorescence observed at a ligand concentration; Fo is fluorescence in the absence of ligand. 10-FDDF as a ligand: FDH (closed circles), NH2-terminal domain (open circles); DDF as a ligand: FDH (closed squares), NH2-terminal domain (open squares). Binding with both ligands is shown on one plot for direct comparison. The slopes of the lines (least squares fit) gave a Kd which were almost the same for FDH and its NH2-terminal domain and were approximately 6.0 nM for 10-FDDF binding and 300 nM for DDF binding.
[View Larger Version of this Image (16K GIF file)]


Analysis of the NH2-terminal Domain Oligomeric Structure

We investigated the oligomeric structure of the NH2-terminal domains using size-exclusion chromatography on a Sephacryl S-300 column. For this purpose, medium after expression of the NH2-terminal domain and without any preceding purification steps was applied to a Sephacryl S-300 column, and hydrolase activity was measured. Fig. 7 shows that maximum hydrolase activity coincided with a protein of about 35 kDa. SDS-PAGE and immunoblot analysis of the eluted fractions have also confirmed that the NH2-terminal domain was eluted in a position coinciding with a protein of about 35 kDa molecular mass (Fig. 7), corresponding to the protein monomer.


Fig. 7. Sephacryl S-300 chromatography of NH2-terminal domains. Culture medium after expression of the NH2-terminal domain (left panel) was applied to a Sephacryl S-300 column, A280 was monitored to determine bovine serum albumin peak (solid line), and 10-FDDF hydrolase activity (nmol/min/ml, open circles) of collected fractions (4 ml) was measured. The column was calibrated in a separate run with a calibration kit (Pharmacia). Arrows show position of standards from this run: blue dextran, 2,000 kDa (I); bovine serum albumin, 67 kDa (II); and chymotrypsinogen A, 25 kDa (III). Right panel shows Coomassie-stained gel (top) and immunoblot stained with antiserum against FDH (bottom) after SDS-PAGE of the indicated fractions (lanes 1-6). Arrow shows position of the NH2-terminal domain. St, protein standards as in Fig. 2.
[View Larger Version of this Image (19K GIF file)]


Study of Interaction between COOH- and NH2-terminal Domains

To determine whether the COOH- and NH2-terminal domains together can combine to produce 10-FTHF dehydrogenase activity, we measured the activity in the presence of both proteins. No 10-FTHF dehydrogenase activity was found when the two domains were mixed. To investigate whether the two domains can interact in the absence of the intermediate domain, we expressed both the COOH- and NH2-terminal domains together. SDS-PAGE analysis of the culture medium showed that both recombinant proteins were expressed (data not shown). The medium was applied to a Sephacryl S-300 column, and all three FDH enzyme activities were assayed in collected fractions. Aldehyde dehydrogenase activity was found in fractions corresponding to a tetramer of the COOH-terminal domain, and 10-FTHF hydrolase activity was observed in fractions corresponding to the NH2-terminal domain monomer (data not shown). No 10-FTHF dehydrogenase activity was found in any of the collected fractions nor did any fraction contain both aldehyde dehydrogenase and hydrolase activities together. SDS-PAGE analysis confirmed that the COOH- and NH2-terminal domains resided in different fractions. These experiments prove that COOH- and NH2-terminal domains do not interact in the absence of the intermediate domain.


DISCUSSION

FDH consists of an NH2-terminal domain, an intermediate domain, and a COOH-terminal domain (1). We have recently expressed the COOH-terminal domain which has 48% identity with aldehyde dehydrogenase (12) and showed that this domain bears an NADP+ binding site and a dehydrogenase catalytic center but has no folate binding site. The intermediate domain is not believed to be directly involved in catalysis but serves to bring the functional COOH- and NH2-terminal domains together in the correct orientation. Earlier, we reported that mutation of cysteine 707 of FDH, which is located in the COOH-terminal domain and thought to be the dehydrogenase catalytic center nucleophile, to alanine abolished the dehydrogenase activity, but the hydrolase activity remained (17). Based upon this information, we predicted that 10-FTHF hydrolase activity resides in the NH2-terminal domain while 10-FTHF dehydrogenase activity is a result of the action of the aldehyde dehydrogenase catalytic site on the folate substrate bound to the NH2-terminal domain. We expressed two NH2-terminal peptides, one contained 203 amino acids that corresponds to the length of GAR-transformylase and the other contained 310 amino acids that corresponds to the length of MFT from E. coli. MFT shares higher identity with the NH2-terminal domain of FDH than GAR-transformylase does, 32 (Fig. 8) and 27%, respectively. It also has a sequence similar to the putative 10-FTHF binding motif. There is only one conservative change, that of a proline to a glycine (Fig. 8). MFTs from several other species have proline in this position, confirming conservation of the sequence. FDH and MFT also have a higher identity in this region than FDH and GAR-transformylase (Fig. 8).


Fig. 8. Alignments of rat liver FDH and E. coli L-methionyl-tRNA formyltransferase and putative folate-binding site. The sequences were initially aligned by BLASTP (25). Identical residues are indicated by vertical lines while conservative changes are identified by +. Spaces (indicated by dashes) were introduced to improve the alignment. Rat FDH sequence of residues 1- 310 was taken from Swiss-Prot P28037[GenBank]. E. coli L-methionyl-tRNA formyltransferase (MFT) sequence was taken from PIR S23108[GenBank]. GART, E. coli GAR-transformylase. The putative 10-FTHF binding motif is in boldface type.
[View Larger Version of this Image (44K GIF file)]


We were surprised to find that the expressed 203 amino acid residue NH2-terminal domain was completely insoluble. The sequence does not contain regions that are highly hydrophobic, and it is not a membrane protein. This suggested that the protein was not folded appropriately. In contrast, the expressed 310-amino acid NH2-terminal protein was soluble and possessed properties that were inherent in the entire enzyme; it contained a folate binding site and displayed 10-FDDF hydrolase activity, suggesting it was folded appropriately. This extends the putative NH2-terminal domain to about 310 amino acid residues rather than the 203 residues derived by comparison with GAR-transformylase. The folate binding parameters and kinetics of the hydrolase reaction were similar for both the NH2 terminus and the complete enzyme. The reaction had the same pH dependence and had a strict requirement for 2-ME. Using the quenching of tryptophan fluorescence, we found that the NH2-terminal domain does not have an NADP+ binding site. The NH2-terminal domain exists as a monomer, unlike the E. coli formyltetrahydrofolte hydrolase enzyme, with the same catalytic function that exists as a hexamer (9).

Although our results showed that the folate binding site is present in the NH2-terminal domain and previously we also showed that the COOH-terminal domain of FDH has no folate binding site (12), the possibility could not be excluded that another folate binding site might be formed from the participation of the two functional domains. However, results obtained after fluorescence titration using DDF or 10-FDDF revealed that there is no difference in substrate binding between FDH and its NH2-terminal domain. This supports the conclusion that only the NH2-terminal domain is involved in substrate binding while the COOH-terminal domain has neither a folate binding site nor participates in formation of such a site together with the other domains. The formyl group of the folate substrate bound to its binding site in the NH2-terminal domain must be accessible to the dehydrogenase catalytic center, and this leads to the conclusion that this group must protrude above the surface of the NH2-terminal domain or at least be close to the surface. This assumes that the pteroyl moiety plays the main role in the interactions of the substrate with the FDH folate binding site. This suggestion is consistent with data obtained from the crystal structure of GAR-transformylase complexed with 5-deazatetrahydrofolate that showed that the pterin part of the folate is well ordered deep in the hydrophobic cleft between the NH2- and COOH-terminal domains of the enzyme, the benzoyl ring is less ordered, and glutamate moiety is at the enzyme surface and is disordered (18). Both FDH (16) and GAR-transformylase (19) can utilize 10-FDDF instead of 10-FTHF as a formyl donor, suggesting structural similarity between the folate-binding sites of the two enzymes. 10-FDDF binds to FDH and its NH2-terminal domain 50-fold more tightly than DDF, probably because of some enhancement of binding by the formyl group. Calculation of the difference between free energies for binding substrate, 10-FDDF, and product, DDF, gives a difference in Delta G of 2.3 kcal/mol. This corresponds to a hydrogen bond energy that is in the range of 2-5 kcal/mol (20) and suggests that the formyl group of the folate substrate forms a hydrogen bond with the protein in the active site. Either hydrogen or oxygen of the formyl group could be a candidate for bond formation. The resolved crystal structure of GAR-transformylase (4) showed that such a hydrogen bond can be formed with His108 or Asp144 of GAR-transformylase (corresponding to His106 and Asp142 for FDH), which are strictly conserved in proteins using 10-FTHF as a formyl donor (1). Possible reasons for such hydrogen bonding of the formyl group in the catalytic mechanism of FDH could be to limit the flexibility of the group, to create stress in the structure of the substrate, and to facilitate the nucleophilic attack and intermediate hemiacetal complex formation during the dehydrogenase/hydrolase reaction (2).

One discrepancy with previous reports was found from the measurement of ligand binding. Previous studies reported (21) that the product of the reaction catalyzed by FDH, THF, binds more tightly to the enzyme than the substrate, 10-formyl-THF, while we show here that the substrate was bound with 50 times higher affinity than was the product of the reactions. The previous study, however, did not measure the binding constant for the substrate, probably due to the instability of the natural substrate, 10-FTHF, and because of the hydrolase reaction that converts 10-FTHF to THF and formate. In the present study, we avoided these problems by using the stable substrate analogue, 10-FDDF, and performed the analysis in the absence of 2-ME so that the hydrolase reaction did not proceed.

The data obtained concerning the domain structure of FDH suggests the following topography for the native protein (Fig. 9). The COOH-terminal domain of the enzyme has sites responsible for the protein oligomerization and bears the NADP+ binding site and the aldehyde dehydrogenase active site, which acts as a catalytic center in the dehydrogenase reaction utilizing 10-FTHF when bound to the adjacent NH2-terminal domain. The NH2-terminal domain can now be extended to about the first 310 amino acid residues and bears a folate binding site and the hydrolase catalytic center. The intermediate domain (which now is shortened to about a hundred amino acid residues) is necessary to bring the two functional domains together to carry out the 10-FTHF dehydrogenase reaction. The two functional domains apparently do not form multiple and close contacts to each other. That was shown by the absence of interdomain complexes, and only the presence of the intermediate domain brings them into the correct orientation. We would like to mention that the intermediate domain (residues 313-403) is enriched with negatively charged amino acid residues, glutamic acid (17.6 versus 6.5% for combined NH2- and COOH-terminal domains) and aspartic acid (8.8 versus 4.7% for NH2 and COOH-terminal domains). Thus, we suggest that electrostatic interactions provided by the intermediate domain could be major contributors to the orientation of the NH2- and COOH-terminal domains in native FDH. Additionally, the fact that the two functional domains not only can function separately but also can be folded separately to produce functional proteins supports the idea that FDH has evolved from a fusion of two different genes, one of which codes for aldehyde dehydrogenase while the other is not yet identified. Our study still leaves open the question of whether the intermediate domain of FDH functions merely as a bridge that brings the two enzymatic domains together to create a new enzyme function or whether it also plays a regulatory role to modulate activity in response to changes in physiological conditions.


Fig. 9. Diagrammatic model of FDH structural organization. Numbers on the scheme show positions of amino acid residues.
[View Larger Version of this Image (70K GIF file)]



FOOTNOTES

*   This work was supported by Grants DK15289, DK46788,and DK49563 of the U. S. Public Health Service and by the Medical Research Service of the Department of Veterans Affairs.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
§   To whom correspondence should be addressed: 612 LH, Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, TN 37232-0146. Tel.: 615-322-6345; Fax: 615-343-0704.
1   The abbreviations used are: FDH, 10-formyltetrahydrofolate dehydrogenase; GAR-transformylase, glycinamide ribonucleotide transformylase; MFT, E. coli L-methionyl-tRNA formyltransferase; 10-FTHF, 10-formyltetrahydrofolate; THF, tetrahydrofolate; 10-FDDF, 10-formyl-5,8-dideazafolate; DDF, 5,8-dideazafolate; 2-ME, 2mercaptoethanol; PAGE, polyacrylamide gel electrophoresis.

REFERENCES

  1. Cook, R. J., Lloyd, R. S., and Wagner, C. (1991) J. Biol. Chem. 266, 4965-4973 [Abstract/Free Full Text]
  2. Cook, R. J., and Wagner, C. (1995) Arch. Biochem. Biophys. 321, 336-344 [CrossRef][Medline] [Order article via Infotrieve]
  3. Gullion, J-M., Mechulam, Y., Schmitter, J-M., Blanquet, S., and Fayat, G. (1992) J. Bacteriol. 174, 4294-4301 [Abstract]
  4. Klein, C., Chen, P., Arevalo, J. H., Stura, E. A., Marolewski, A., Warren, M. S., Benkovic, S. J., and Wilson, I. A. (1995) J. Mol. Biol. 249, 153-175 [CrossRef][Medline] [Order article via Infotrieve]
  5. Warren, M. S., Marolewski, A. E., and Benkovic, S. J. (1996) Biochemistry 35, 8855-8862 [CrossRef][Medline] [Order article via Infotrieve]
  6. Scrutton, M. C., and Beis, I. (1979) Biochem. J. 177, 833-846 [Medline] [Order article via Infotrieve]
  7. Rios-Orlandi, E. M., Zarkadas, C. G., and MacKenzie, R. E. (1986) Biochim. Biophys. Acta 87, 24-35
  8. Nagy, P. L., McCorkle, G. M., and Zalkin, H. (1993) J. Bacteriol. 175, 7066-7073 [Abstract]
  9. Nagy, P. L., Marolewski, A., Benkovic, S. J., and Zalkin, H. (1995) J. Bacteriol. 177, 1292-1298 [Abstract]
  10. Schirch, D., Villar, E., Maras, B., Barra, D., and Schirch, V. (1994) J. Biol. Chem. 269, 24728-24735 [Abstract/Free Full Text]
  11. Wagner, C., Briggs, W. T., Horne, D. W., and Cook, R. J. (1995) Arch. Biochem. Biophys. 316, 141-147 [CrossRef][Medline] [Order article via Infotrieve]
  12. Krupenko, S. A., Wagner, C., and Cook, R. J. (1997) J. Biol. Chem. 272, 10266-10272 [Abstract/Free Full Text]
  13. Krupenko, S. A., Horstman, D. A., Wagner, C., and Cook, R. J. (1995) Protein Expression Purif. 6, 457-464 [CrossRef][Medline] [Order article via Infotrieve]
  14. Cook, R. J., and Wagner, C. (1982) Biochemistry 21, 4427-4434 [Medline] [Order article via Infotrieve]
  15. Cook, R. J., and Wagner, C. (1986) Methods Enzymol. 122, 251-255 [Medline] [Order article via Infotrieve]
  16. Krupenko, S. A., Wagner, C., and Cook, R. J. (1995) Biochem. J. 306, 651-655 [Medline] [Order article via Infotrieve]
  17. Krupenko, S. A., Wagner, C., and Cook, R. J. (1995) J. Biol. Chem. 270, 519-522 [Abstract/Free Full Text]
  18. Almassy, R. J., Janson, C. A., Kan, C.-C., and Hostomska, Z. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 6114-6118 [Abstract]
  19. Smith, G. K., Mueller, W. T., Benkovic, P. A., and Benkovic, S. J. (1981) Biochemistry 20, 1241-1245 [Medline] [Order article via Infotrieve]
  20. Atkins, W. M., and Sligar, S. G. (1988) J. Biol. Chem. 263, 18842-18849 [Abstract/Free Full Text]
  21. Min, H., Shane, B., and Stokstad, E. L. R. (1988) Biochim. Biophys. Acta 967, 348-353 [Medline] [Order article via Infotrieve]
  22. Needleman, S., and Wunsch, C. (1979) J. Mol. Biol. 48, 444-453
  23. Chow, S. F., and Horowitz, P. M. (1985) J. Biol. Chem. 260, 15516-15521 [Abstract/Free Full Text]
  24. Eftink, M. R., and Ghiron, C. A. (1981) Anal. Biochem. 114, 199-227 [Medline] [Order article via Infotrieve]
  25. Altschul, S. F., Gish, W., Miller, W., Myers, E. W., and Lipman, D. J. (1990) J. Mol. Biol. 215, 403-410 [CrossRef][Medline] [Order article via Infotrieve]

©1997 by The American Society for Biochemistry and Molecular Biology, Inc.